Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: Feasibility and tolerability in a subset of patients in a randomized trial

Critical Reviews in Oncology/Hematology

Volumn 58, Issue 2, 2006, Pages 166-175

  Kümmel, Sherko ^a   Krocker, Jutta ^b   Kohls, Andreas ^c   Breitbach, Georg Peter ^d   Morack, Günther ^e   Budner, Marek ^f   Blohmer, Jens Uwe ^b   Lichtenegger, Werner ^g   Elling, Dirk ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MARTIN LUTHER KRANKENHAUS   (Germany)

^c Evangelisches Krankenhaus Ludwigsfelde Teltow   (Germany)

^d Staedtisches Klinikum Neunkirchen GmbH   (Germany)

^e HELIOS KLINIKUM BERLIN BUCH   (Germany)

^f Humaine Klinikum Bad Saarow   (Germany)

^g Krankenhaus ^*

Author keywords

Breast cancer; Chemotherapy; Elderly; Filgrastim

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANEMIA; AXILLARY LYMPH NODE; BLOOD TOXICITY; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; RANDOMIZATION; RETROSPECTIVE STUDY; REVIEW; THERAPY DELAY; THROMBOCYTOPENIA;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEASIBILITY STUDIES; FEMALE; FILGRASTIM; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 33748249873     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2005.08.009     Document Type: Review

References (27)

1. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
2. Hutchins L.F., Unger J.M., Crowley J.J., et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341 (1999) 2061-2067
3. Giordano S.H., Hortobagyi G.N., Kau SW.C., et al. Breast cancer treatment guidelines in older women. J Clin Oncol 23 (2005) 783-791
4. Mandelblatt J.S., Hadley J., Kerner J.F., et al. Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. Cancer 89 (2000) 561-573
5. DeMichele A., Putt M., Zhang Y., et al. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma. Cancer 97 (2003) 2150-2159
6. Djordjevic N., Karanikolic A., and Pesic M. Breast cancer in elderly women. Arch Gerontol Geriatr 39 (2004) 291-299
7. Gajdos C., Tartter P.I., Bleiweiss I.J., et al. The consequence of undertreating breast cancer in the elderly. J Am Coll Surg 192 (2001) 698-707
8. Bouchardy C., Rapiti E., Fioretta G., et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 21 (2003) 3580-3587
9. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352 (1998) 930-942
10. Poole C.J., Earl H.M., Dunn J.A., et al. NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF. Presented at the American Society of Clinical Oncology. May 31-June 1, Chicago, IL (2003) [abstract 13, International Breast Cancer Study Group]
11. International Breast Cancer Study Group (IBSCG). Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 94 (2002) 1054-1065
12. Muss H.B., Woolf S.H., Berry D.A., et al. Older women with node positive (N+) breast cancer (BC) get similar benefits from adjuvant chemotherapy (Adj.) as younger patients (pts): The Cancer and Leukemia Group B (CALGB) experience, ASCO. Proc Am Soc Clin Oncol (2003) 4
13. Wildiers H., and Paridaens R. Taxanes in elderly breast cancer patients. Cancer Treat Rev 30 (2004) 333-342
14. Bonadonna G. Current and future trends in the multidisciplinary approach for high-risk breast cancer: the experience of the Milan Cancer Institute. Eur J Cancer 32A 2 (1996) 209-214
15. Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21 (2003) 976-983
16. Glück S. The worldwide perspective in the adjuvant treatment of primary lymph-node-positive breast cancer. Breast Cancer 8 (2001) 321-328
17. Lück H.J., Thomssen C., duBois A., et al. Interim analysis of a phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer. Semin Oncol 23 1 Suppl. 1 (1996) 33-36
18. Roché H., Fumoleau P., Spielmann M., et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. 27th annual San Antonio breast cancer symposium. December 10 (2004)
19. Bonadonna G., Valagussa P., Moliterni A., Zambetti M., and Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332 (1995) 901-906
20. The Cancer and Leukemia Group B, Budman D.R., Berry D.A., Cirrincione C.T., et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 90 (1998) 1205-1211
21. Citron M.L., Berry D.A., Cirrincione C., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21 (2003) 1431-1439
22. Hudis C., Seidman A., Raptis G., et al. Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 23 (1996) 58-64
23. Lyman G.H., Dale D.C., and Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21 (2003) 4524-4531
24. Repetto L., Biganzoli L., Koehne C.H., et al. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 39 (2003) 2264-2272
25. Sobin L.H., and Wittekind C. International union against cancer. TNM classification of malignant tumours (1997), J. Wiley, New York
26. Vogel C.L., Wojtukiewicz M.Z., Carroll R.R., et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23 (2005) 1178-1184
27. Holmes F.A., O'Shaughnessy J.A., Vukelja S., et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20 (2002) 727-731